Scarica l'app Stockscreener
3.26
1.24%
0.04
Dopo l'orario di chiusura:
3.16
-0.10
-3.07%
Precedente Chiudi:
$3.22
Aprire:
$3.19
Volume 24 ore:
3.61M
Relative Volume:
0.30
Capitalizzazione di mercato:
$429.61M
Reddito:
-
Utile/perdita netta:
$-35.47M
Rapporto P/E:
-5.7193
EPS:
-0.57
Flusso di cassa netto:
$-124.27M
1 W Prestazione:
-7.39%
1M Prestazione:
+405.27%
6M Prestazione:
+89.53%
1 anno Prestazione:
+55.24%
Intervallo 1D:
$3.06
$3.33
Intervallo di 1 settimana:
$2.87
$3.56
Portata 52W:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Nome
Prokidney Corp
Settore
Industria
Telefono
336-999-7028
Indirizzo
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Confronta PROK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
3.26 | 429.61M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Iniziato | JP Morgan | Neutral |
| 2024-09-10 | Iniziato | Guggenheim | Buy |
| 2024-03-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-07-25 | Iniziato | BTIG Research | Buy |
| 2022-12-21 | Iniziato | Jefferies | Buy |
| 2022-11-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Iniziato | UBS | Buy |
| 2022-10-14 | Iniziato | Citigroup | Buy |
| 2022-09-23 | Iniziato | BofA Securities | Buy |
| 2022-09-02 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Prokidney Corp Borsa (PROK) Ultime notizie
Prokidney’s REACT Study: A Promising Step for Kidney Disease Treatment - TipRanks
Meet the Biotech Stock That Rocketed 775% Higher - MSN
Is ProKidney Corp. a good long term investmentGame-changing returns - Autocar Professional
What drives ProKidney Corp. stock priceHigh-octane financial growth - Autocar Professional
BlackRock, Inc. Reduces Stake in ProKidney Corp: A Strategic Por - GuruFocus
What analysts say about ProKidney Corp. stockExplosive trading growth - jammulinksnews.com
ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement - MSN
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
ProKidney Corp. Stock Analysis and ForecastDynamic profit expansion - Autocar Professional
JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK) - MSN
ProKidney Corp. (PROK): Navigating Clinical Pivotality and Market Volatility in the Race for a CKD Breakthrough - AInvest
JP Morgan Maintains Neutral Stance on ProKidney Corp., Citing Extended Timeline for Key Data - AInvest
New Strong Buy Stocks for July 17th - MSN
10 Hot Penny Stocks to Invest in Now - Insider Monkey
ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? - Mitrade
Best Momentum Stocks to Buy for July 17th - Nasdaq
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
ProKidney gains pivotal therapy advancement step with FDA - Winston-Salem Journal
ProKidney completes Delaware domestication and restructures corporate agreements By Investing.com - Investing.com Nigeria
ProKidney completes Delaware domestication and restructures corporate agreements - Investing.com
Citi Maintains ProKidney(PROK.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Will ProKidney’s Recent Surge Last? - StocksToTrade
ProKidney’s Clinical Trials and Regulatory Developments Lead to Hold Rating Amid Uncertainty - TipRanks
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
ProKidney’s Hold Rating: Balancing FDA Alignment and Extended Approval Timeline - TipRanks
ProKidney’s Strategic FDA Alignment and Promising Clinical Data Drive Buy Rating - TipRanks
ProKidney stock soars after FDA confirms accelerated approval pathway - Investing.com
ProKidney price target raised to $7 from $6 at Guggenheim - MSN
ProKidney’s Dramatic Shares Tumble - timothysykes.com
Is ProKidney’s Slide a Buy Signal? - StocksToTrade
ProKidney Shares Plummet Amid Downgrades - timothysykes.com
UBS Initiates ProKidney(PROK.US) With Buy Rating, Announces Target Price $8 - 富途牛牛
ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial - MarketScreener
ProKidney Stock Skyrockets: What Does This Mean? - StocksToTrade
ProKidney, FDA align on accelerated approval pathway for Rilparencel - MSN
Prokidney Corp Azioni (PROK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):